Loading stock data…
EXOZ
$9.75-0.23 (-2.30%)
Market ClosedLast close May 1
eXoZymes, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
eXoZymes, Inc. in the Healthcare sector is trading at $9.75. The stock is currently 47% below its 52-week high of $18.40, remaining 13.6% below its 200-day moving average. Technical signals show oversold RSI of 18 and bearish MACD signal, explaining why EXOZ maintains its current current market pressure. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 18) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$9.75
Potential Upside
5%
Whystock Fair Value$10.24
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
eXoZymes, Inc. operates as a development stage biotechnology company. The company focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technolo...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$87.32M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-269.59%
Volume
Today's trading volume
10,978
Recent News
MDB Capital Holdings LLC (MDBH) Q4 2025 Earnings Call Highlights: Strategic Innovations and ...
Discover how MDB Capital Holdings LLC (MDBH) is leveraging AI and strategic investments to navigate market challenges and drive future growth.
EXoZymes Inc (EXOZ) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
EXoZymes Inc (EXOZ) showcases its innovative biomanufacturing platform and strategic focus on NCT and cannabinoids, while navigating financial hurdles and market skepticism.
eXoZymes Q4 Earnings Call Highlights
Executives at eXoZymes (NASDAQ:EXOZ) used the company’s latest investor call to outline how management is prioritizing a narrower set of commercial opportunities, led by its NCT program and a cannabinoid pipeline, while preparing for a new financing round and continuing to develop its cell-free biom
EXoZymes Inc (EXOZ) Q3 2025 Earnings Call Highlights: Unlocking Market Opportunities Amid ...
EXoZymes Inc (EXOZ) showcases innovative breakthroughs and strategic partnerships while navigating financial hurdles and regulatory risks.
Wall Street Set to Open Higher Wednesday as Key Inflation Measure Declines
US stocks look set to open higher in Wednesday's trading session after a key inflation measure unexp